Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Atara Biotherapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 109 | 1 | 91 | −17 |
| Shares | 88.2M | 1.00M | 64.7M | −22.5M (−25.8%) |
| Value | $130.5M | $1.48M | $33.2M | −$95.8M (−74.3%) |
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| EcoR1 Capital, LLC | 10,067,043 | $5.16M | 0.13% |
| Gsa Capital Partners LLP | 784,367 | $402.0K | 0.03% |
| Marshall Wace, LLP | 292,500 | $149.2K | 0.00% |
| Two Sigma Investments, LP | 129,184 | $66.2K | 0.00% |
| HRT Financial LP | 117,267 | $60.0K | 0.00% |
| Vontobel Holding Ltd. | 80,000 | $41.0K | 0.00% |
| Two Sigma Securities, LLC | 68,243 | $35.0K | 0.00% |
| Point72 Middle East FZE | 35,536 | $18.2K | 0.00% |
| Wexford Capital LP | 29,940 | $15.4K | 0.00% |
| Prudential Financial Inc | 26,838 | $13.8K | 0.00% |
| State Board of Administration of Florida Retirement System | 25,159 | $12.9K | 0.00% |
| Commonwealth Equity Services, LLC | 16,293 | $8.00K | 0.00% |
| Neuberger Berman Group LLC | 11,137 | $5.71K | 0.00% |
| StoneX Group Inc. | 10,000 | $5.13K | 0.00% |
| Baader Bank INC | 10,942 | $4.16K | 0.00% |
| Federated Hermes, Inc. | 474 | $243 | 0.00% |
| The PNC Financial Services Group, Inc. | 59 | $30 | 0.00% |
| Farther Finance Advisors, LLC | 1 | $1 | 0.00% |
Sold out (35)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
Not filed for Q4 2023 yet (1)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Antipodean Advisors LLC | 1,000,000 | $1.48M |